CEBPA and acute myeloid leukemia: The WHO classification of AML includes many specific chromosomal abnormalities determined by karyotyping (11). The gene mutations recognized as specific entities by the 2016 WHO classification include NPM1, CEBPA, and RUNX1 mutations. However, since the publication of this classification, it became very important to clinically recognize other pathogenic variants such as those involving FLT3 (ITD and TKD) and IDH1/2.